Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The protein kinase AKT1 regulates multiple signaling pathways essential for cell function. Its N-terminal PH domain (AKT1 PH) binds the rare signaling phospholipid phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P(3)], resulting in plasma membrane targeting and phosphoactivation of AKT1 by a membrane-bound kinase. Recently, it was discovered that the Glu17Lys mutation in the AKT1 PH domain is associated with multiple human cancers. This mutation constitutively targets the AKT1 PH domain to the plasma membrane by an unknown mechanism, thereby promoting constitutive AKT1 activation and oncogenesis. To elucidate the molecular mechanism underlying constitutive plasma membrane targeting, this work compares the membrane docking reactions of the isolated wild-type and E17K AKT1 PH domains. In vitro studies reveal that the E17K mutation dramatically increases the affinity for the constitutive plasma membrane lipid PI(4,5)P(2). The resulting PI(4,5)P(2) equilibrium affinity is indistinguishable from that of the standard PI(4,5)P(2) sensor, PLCdelta1 PH domain. Kinetic studies indicate that the effects of E17K on PIP lipid binding arise largely from electrostatic modulation of the dissociation rate. Membrane targeting analysis in live cells confirms that the constitutive targeting of E17K AKT1 PH to plasma membrane, like PLCdelta1 PH, stems from PI(4,5)P(2) binding. Overall, the evidence indicates that the molecular mechanism underlying E17K oncogenesis is a broadened target lipid selectivity that allows high-affinity binding to PI(4,5)P(2). Moreover, the findings strongly implicate the native Glu17 side chain as a key element of PIP lipid specificity in the wild-type AKT1 PH domain. Other PH domains may employ an analogous anionic residue to control PIP specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535 · cited 1×
“For example, on the cytoplasmic surface of the plasma membrane, the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases convert a constitutive PIP lipid, phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2],1 into the rare second-messenger lipid phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] (1,6,7).”
BackgroundVárnai, P., & Balla, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.501 · Cited by 859
Stauffer, T. P., Ahn, S., & Meyer, T. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70135-6 · Cited by 761
Signalling through Class I PI3Ks in mammalian cells
Hawkins, P. T., Anderson, K. E., Davidson, K., & Stephens, L. R. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340647 · Cited by 540 · cited 1×
“For example, on the cytoplasmic surface of the plasma membrane, the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases convert a constitutive PIP lipid, phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2],1 into the rare second-messenger lipid phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] (1,6,7).”
BackgroundIsakoff, S. J., Cardozo, T., Andreev, J., Li, Z., Ferguson, K. M., Abagyan, R., Lemmon, M. A., Aronheim, A., & Skolnik, E. Y. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5374 · Cited by 324
Pleckstrin homology (PH) domains and phosphoinositides
Lemmon, M. A. (2007) · Biochemical Society Symposium · doi:10.1042/bss0740081 · Cited by 298
Várnai, P., Rother, K. I., & Balla, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10983 · Cited by 295 · cited 1×
“In fact, the E41K mutant of the Btk PH domain is also known to generate constitutive plasma membrane targeting via an unknown mechanism (38): we propose this mutation increases affinity for PI(4,5)P2 in the same manner as E17K in the AKT1 PH domain.”
BackgroundEvans, J. H., & Falke, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707719104 · Cited by 151
Self-citationGolebiewska, U., Nyako, M., Woturski, W., Zaitseva, I., & McLaughlin, S. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-12-1208 · Cited by 140
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wu, W.-I., Voegtli, W. C., Sturgis, H. L., Dizon, F. P., Vigers, G. P. A., & Brandhuber, B. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012913 · Cited by 331
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
The Role of mTOR Signaling as a Therapeutic Target in Cancer
Popova, N. V., & Jücker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041743 · Cited by 267
Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway
Jethwa, N., Chung, G. H. C., Lete, M. G., Alonso, A., Byrne, R. D., Calleja, V., & Larijani, B. (2015) · Journal of Cell Science · doi:10.1242/jcs.172775 · Cited by 68
PH domain-mediated autoinhibition and oncogenic activation of Akt
Bae, H., Viennet, T., Park, E., Chu, N., Salguero, A., Eck, M. J., Arthanari, H., & Cole, P. A. (2022) · eLife · doi:10.7554/elife.80148 · Cited by 31
Metadata
- Authors
- Landgraf, K. E., Pilling, C., & Falke, J. J.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-10-28
- Volume
- 47
- Issue
- 47
- Pages
- 12260-12269
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2065674479
- Cited by
- 99
- References
- 10
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.